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Summary The purpose of this study was to compare alpha-L-fucosidase and alpha-fetoprotein as serum
markers of hepatocellular carcinoma in 72 southern African blacks with this tumour and 64 matched patients
with benign hepatic diseases which might be mistaken clinically for hepatocellular carcinoma. Alpha-L-
fucosidase activity was assayed using p-nitrophenyl-L-fucopyranoside (pNpf) as a substrate and alpha-
fetoprotein concentrations were measured by radioimmunoassay. Serum alpha-L-fucosidase activity in the
patients with hepatocellular carcinoma (mean 1,268, s.e.m.+ 83.7, median 1,150 and range 38-3,698nmol
pNpfml - h-1) was significantly higher than that in the matched controls (mean 798, s.e.m.+65.8, median
648 and range 273-3,825nmol pNpfml-l h-1) (P=0.0001). However, alpha-L-fucosidase was both less
sensitive (75 versus 87%) and less specific (70 versus 87%) than alpha-fetoprotein as a serum marker of
hepatocellular carcinoma. When, in an endeavour to eliminate false-positive results, the diagnostic cut-off
level for alpha-L-fucosidase was increased to 1,500nmol pNpfml-' h-1 and for alpha-fetoprotein to
400ngml-1, the sensitivity of alpha-L-fucosidase fell to 21% whereas that of alpha-fetoprotein remained
satisfactory at 78%. If the two markers were used together, the number of false-negative alpha-fetoprotein
results was reduced from 13 to 5.5%. We conclude that alpha-L-fucosidase is less useful than alpha-
fetoprotein as a single marker of hepatocellular carcinoma in southern African blacks. However, the two
markers can profitably be used together.
The lysosomal hydrolase, alpha-L-fucosidase (alpha-L-
fucoside fucohydrolase; 3.2.1.51; AFU), is present in many
mammalian tissues where it degrades fucose-containing
glycoconjugates. A number of isomers of the enzyme have
been identified in human tissues, including two hepatic forms
(Robinson & Thorpe, 1973). The clinical importance of AFU
is indicated by the occurrence, albeit rare, of a deficiency
state that results in a neurovisceral storage disease known as
fucosidosis (Durand et al., 1969), and by the observation
that women with low serum activity of the enzyme may be
prone to ovarian carcinoma (Lynch et al., 1985). Raised
serum concentrations of AFU have been described in
patients with a variety of benign diseases, including diabetes,
hyperthyroidism, toxic oil syndrome and, of particular rele-
vance to the present study, cirrhosis, alcoholic hepatitis and
acute viral hepatitis (Reglero et al., 1980; Calvo et al., 1982;
Guillou et al., 1982; Cabezas-Delamore et al., 1983;
Deugnier et al., 1984; DiCioccio et al., 1985). Increased AFU
activity has also been reported in association with carcinoma
of the lung, breast, stomach, ovary and uterus and, more
recently, with hepatocellular carcinoma (HCC) (Reglero et
al., 1980; Calvo et al., 1982; Deugnier et al., 1984; DiCioccio
et al., 1985). Deugnier and his colleagues (1984) found serum
levels of AFU to be raised in European patients with HCC
more often than serum concentrations of alpha-fetoprotein
(AFP), although they cautioned that studies in larger
numbers of patients were needed before liver cancer specifi-
city could be assigned to AFU. However, DiCioccio et al.
(1985) were later unable to distinguish between HCC and
cirrhosis in North American patients on the basis of serum
AFU concentrations. The purpose of this study was to
compare AFU and AFP as serum markers of HCC in
southern African blacks, a population that has both a high
incidence of the tumour and in which AFP is a more useful
tumour marker than it is in 'western' populations with a low
incidence of HCC (Kew & Newberne, 1982).
Patients and methods
Sera from 53 apparently healthy southern African blacks and
28 South African caucasians were assayed for AFU activity
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in order to establish the normal serum AFU concentrations
in these populations. Sera were also obtained from 72
southern African blacks with histologically proved HCC and
64 race, sex and age-matched patients with benign hepatic
disease (33 with hepatitis B virus-related chronic active or
chronic persistent hepatitis, or active cirrhosis; 13 with
alcoholic hepatitis or cirrhosis; 10 with amoebic hepatic
abscesses; and eight with miscellaneous conditions). The
patients with chronic hepatic parenchymal disease showed no
clinical, ultrasonographic or scintigraphic evidence of a
superimposed HCC. Blood for assay was drawn from the
patients with HCC before cancer chemotherapy was started.
Serum AFU activity was assayed using a method similar
to that described by Troost et al. (1976). A mixture of
0.25ml of 4mM p-nitrophenyl-L-fucopyranoside (pNpf)
(Sigma Chemical Co, St Louis, MO), 0.5ml 0.2 M sodium
acetate buffer (pH 5.5) and 0.125ml serum was made up to
a final volume of 1 ml with distilled water. The mixture was
incubated at 37°C for 60min, after which the reaction was
inhibited by the addition of 0.2M glycine NaCl (brought to a
pH of 10.7 with sodium hydroxide). Duplicate assay mix-
tures and control assays lacking serum or substrate (pNpf)
made up to a total volume of 1 ml were incubated at 37°C
for 1 h. Absorbance was measured at 400 nm and the
enzymatic activity expressed in nmol pNpfml-I h-. The
resulting absorbance spectrophotometric curve was linear to
an absorbance of 0.8. Samples falling in the range higher
than this were diluted further.
Serum AFP concentrations were measured in the same
patients using radioimmunoassay (Amersham International,
Amersham, UK).
The effects of collection and storage on serum AFU
activity were determined by an analysis of variance and the
significance level was corrected according to the Bonferoni
adjustment (the reason for using this adjustment was that
simultaneous tests were done, necessitating that the level of
significance be adjusted to provide for these comparisons, i.e.
the test level is divided by the number of comparisons being
made) (Rupert & Miller, 1981). The variables tested were
fasting compared with non-fasting (in 12 caucasian subjects),
duration of storage at -20CC (less than 12h compared with
greater than 24h; 1 day compared with 1, 4 and 8 weeks),
and storage at 4°C and -20°C (in 28 caucasian subjects).
The means of the AFU values in the fasting and non-fasting
sera were corrected for storage time. Student's t test was
applied to compare the AFU concentrations in the caucasian
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Table I The effect of storage on serum AFU activity
Time of Serum AFU s.e.m. P
sample least square least square 24h-1 1-4 4-8
testing mean mean Immediate week weeks weeks
Immediate 231.6 8.69
24h-1 week 287.2 8.05 0.0001a
1-4 weeks 298.6 16.08 0.0004a 0.5369
4-8 weeks 326.1 13.26 0.0001a 0.0056 0.2218
8-12 weeks 358.3 14.19 0.0001a 0.0001a 0.0088 0.0816
All samples corrected for patients and fasting in analysis of variance using least square means.
aSignificant at the 5% significance level after Bonferoni adjustment.
Table II Comparison between alpha-L-fuCosidase (AFU) and alpha-
fetoprotein (AFP) ofhepatocellular carcinoma using diagnostic cut-off
levels of 820nmol pNpfml-'h-' for AFU and 20ngml-' for AFP
p
(Fisher's
AFU AFP exact test)
Sensitivitya 75% 87% 0.0469
Specificityb 70% 87% 0.0237
Predictive value of positive testc 74% 90% 0.0121
Predictive value of negative testd 71% 84% 0.0792
true positive Sensitivity true positive+false negative
bSpecificity =
true negative +false positive
true negative+fatrueppositive
cPredictive value of a positive test= true positive
true positive+false positive
'Predictive value of a negative test=
negative
true negative+false negative'
and black controls. The sera from the black and caucasian
subjects were stored under identical conditions. Receiver
operating characteristic (ROC) curves were constructed for
both AFU and AFP, and they were compared using
Student's t test. ROC curves are plots of the percentage true-
positives against the percentage false-positives for multiple
thresholds (Herman et al., 1988). The area under the ROC
curve is indicative of the predictive value of the test. The
differences between sensitivity, specificity and predictive
values of AFU and AFP were compared using Fisher's exact
test.
Results
Effect offasting
No signficant differences were obtained when AFU activity
was compared in blood that had been drawn from the same
control subjects in the fasting (mean 286.8 nmol
pNpfmlP1 h- 1, s.e.m.+0.03) and non-fasting state
(313.9nmol pNpfml -h-1, s.e.m.+5.81) (P=0.0140; this is
not significant when the Bonferoni adjustment is used: P
must be less than 0.005).
Effect of race and sex
AFU activity in serum taken in the non-fasting state from
the 28 caucasian controls was compared with that of the 53
black controls. The activity in the caucasians (median
220.5 nmol pNpfml - h-1, mean 260.5, s.e.m. + 26.8; range
39-678) was significantly lower than that in the blacks
(median 529.9nmol pNpfml-l h-1, mean 517.9, s.e.m.
21.07; range 233-930) (P=0.0001). Possible differences
between the sexes were measured only in the blacks; no
differences were observed (P = 0.431).
Effect of method and duration of storage
Significantly higher serum AFU concentrations were found
in sera which had been stored for longer than 24h in
comparison with sera stored for less than 12h (Table I).
However, no significant differences existed when samples
were stored from 24h up to 8 weeks (Table I). With storage
longer than 8 weeks, differences from the values obtained at
24h were observed (Table I). No differences were found
between sera stored at 4°C and those stored at -20°C
(P> 0.1) when other variables were standardised for.
Comparison between AFU and AFP levels in HCC and
benign hepatic disease
The 72 patients with HCC had serum AFU levels which
ranged from 381 to 3,698 nmol pNpfml -1h - with a median
value of 1,150, mean 1,268 and s.e.m.+83.7. These concen-
trations were significantly higher than those of the patients
with benign hepatic disease (range 273-3,825 nmol
pNpfml-1 h-1, median 648, mean 798, s.e.m. +65.8)
(P=0.0001). Serum AFP concentrations were significantly
higher in the HCC patients (median 2,280, mean 28,071,
s.e.m.+4,702, range 0 to >100,000ngml-1) than in those
with benign hepatic disease (median 1, mean 21.0,
s.e.m.+84.8, range 0-339ngml-1) (P=0.0001). A compari-
son between the sensitivity, specificity and predictive values
of AFU and AFP is shown in Table II. The theta coefficient
(area under the ROC curve, as shown in Figure 1) for AFP
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Figure 1 Receiver operating characteristic curves for serum
alpha-L-fucosidase (*, theta =0.7749) and alpha-fetoprotein (0,
theta=0.9191) concentrations obtained in patients with hepato-
cellular carcinoma and benign hepatic disease in the present
study. The straight line is the chance line.ALPHA-L-FUCOSIDASE AS HEPATOMA MARKER 419
Table III Comparison of random upper limits of serum alpha-L-fuCosidase
activity
Positive Negative
Cut-offpoint predictive predictive
(nmol pNpf ml-l h-1) Sensitivity Specificity value value
550 94 32 60 84
740 82 54 68 75
820 75 70 74 71
940 63 80 77 67
1,200 44 86 78 58
1,500 21 95 83 53
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Figure 2 Serum alpha-L-fuCosidase activity in control subjects,
patients with benign hepatic disease and patients with hepatocel-
lular carcinoma. 820nmol pNpfml-1 h-1 was taken as the upper
limit of the normal range.
(0.9191, s.e.m. +0.0262) was greater than that for AFU
(0.7749, s.e.m.+0.0398) (P=0.0013), confirming that AFP is
a superior marker for HCC. The ideal cut-off point for a
diagnostic value of AFU was determined by random selec-
tion of multiple points from the ROC curve (Table III). The
point considered best (820nmol pNpfml-'h-) was, coinci-
dentally, two standard deviations above the mean value.
Figure 2 illustrates the distribution of serum AFU activity in
the patients at this cut-off level. At this concentration AFU
has a sensitivity in southern African blacks of 75% and a
specificity of 70%. This compares with a sensitivity and a
specificity of 87% for AFP at a level of >20ngml-1
(Table II). At the higher diagnostic cut-off level for AFP of
400 ngml-1, the specificity is 96% and the sensitivity
remains high at 78%. However, when the diagnostic cut-off
level for AFU was increased to achieve a similar specificity
(95%), its sensitivity fell to 21 % (Table III).
Discussion
Normal serum AFU activity ranges between 350 and
660nmol pNpfml - h - (Turner et al., 1975; Troost et al.,
1976; Deugnier et al., 1984). Although not specified, these
values were probably established in caucasian subjects. Not
unexpectedly, we found caucasian subjects living in South
Africa to have similar serum concentrations. Of considerable
interest was our finding of appreciably higher serum levels of
AFU in apparently healthy blacks. This has not previously
been described, and may possibly be explained by racial
differences in the distribution of AFU phenotypes (Turner et
al., 1975). Important too is the effect of storage on serum
AFU activity. Serum AFU concentrations increase, in com-
parison with the value in fresh serum, if the specimen is
stored, frozen or at 4°C, for 24h. Unfortunately, it is
generally impractical in clinical practice to test sera for AFU
activity immediately after the specimen is obtained. The
increase in AFU activity is presumably explained on the
basis of incomplete separation of cells from serum during
centrifugation, with subsequent lysis of these cells and release
of the enzyme during storage. There is no further increase in
serum AFU concentrations when the specimens are stored
for periods ranging up to eight weeks, although the mea-
sured levels do increase again if the sera are stored for
longer than this. Repeated freezing and thawing does not
affect the AFU values (Turner et al., 1975).
Although AFP remains the 'gold standard' against which
other serum markers of HCC must be compared, false-
negative results may occur in 20-30% of patients in regions
with a low incidence of the tumour, and false-positive results
may be seen in patients with undifferentiated terato-
carcinomas or embryonal cell carcinomas of the testis or
ovary, tumours of entodermal origin, and in various forms
of acute and chronic benign hepatic disease (Kew &
Newberne, 1982). The search for an ideal serum marker for
HCC therefore continues.
Deugnier et al. (1984) found raised serum AFU activity to
be both more sensitive and more specific than an elevated
serum AFP concentration as a marker for HCC in French
patients. In the present study involving black patients with
HCC or various benign hepatic diseases which might be
mistaken clinically for HCC, the sensitivity and specificity of
AFU proved to be the same as that reported by Deugnier et
al. (1984). However, AFP is known to be more sensitive in
blacks than in caucasians with HCC (Kew & Newberne,
1982), and this explains our finding that AFP was the better
marker in a black population. Both the study of Deugnier et
al. (1984) and our investigation have shown that the two
markers can profitably be used in conjunction. If this was
done, the percentage of false-negative AFP results in black
patients was reduced from 13 to 5.5 per cent.
If financial constraints are a consideration, AFU is both
cheaper to measure than AFP (less than US$1 per test
compared with more than US$2 per test) and has a lesser
initial outlay for laboratory equipment.
The reason for the increase in serum activity of AFU in
HCC is not known. The most likely explanation is that the
raised serum concentrations result from an increased syn-
thesis of proteins by the tumour with consequent increased
fucose turnover (Vischer & Reutter, 1978; Holmes &
Hakamori, 1982).
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